Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Anti‑proliferative and anti‑inflammatory activities of Struchium sparganophorum (L.) Kuntze (Asteraceae) with UPLC‑QTOF‑MS/MS‑based metabolite profiling.

Created on 14 Nov 2026

Authors

Nam Minh Nguyen, Hau Ngoc Nguyen, Huyen Thi Tran

Published in

Natural product research. Pages 1-9. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Struchium sparganophorum (L.) Kuntze has been traditionally used for wound healing and inflammatory-related conditions, yet its biological activities and phytochemical profile remain insufficiently explored. This study evaluates the antiproliferative and anti-inflammatory activities of its extracts and characterises the most bioactive fraction. The n-hexane extract exhibited the strongest antiproliferative effect against B16F10 melanoma cells with IC50 = 11.72 ± 0.96 µg/mL and induced apoptosis, as evidenced by nuclear condensation and fragmentation in DAPI staining. It also inhibited nitric oxide production by 78.29% at 20 µg/mL in LPS-stimulated RAW 264.7 macrophages. UPLC-QTOF-MS/MS analysis tentatively identified 20 metabolites, including flavonoids, lignans, steroids, terpenoids, and coumarins. Molecular docking against iNOS (PDB: 4CX7) and BRAF kinase (PDB: 6V34) revealed that several compounds exhibited favourable binding interactions, suggesting their contribution to the observed bioactivities. These findings support the potential of S. sparganophorum as a source of bioactive natural products.

PMID:
43024598
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement